Real-World Outcomes and Prognostic Factors Among Patients with Advanced Non-Small Cell Lung Cancer and High PD-L1 Expression Treated with Immune Checkpoint Inhibitors as First-Line Therapy.
Journal Information
Full Title: Cancer Manag Res
Abbreviation: Cancer Manag Res
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Disclosure Wenzhen Ge, Ning Wu, Jessica J Jalbert, Ruben G W Quek, Petra Rietschel, Jean-Francois Pouliot, and James Harnett are employees and shareholders of Regeneron Pharmaceuticals, Inc. Jinjie Liu is an employee of Genesis Research, which provides consulting services to Regeneron Pharmaceuticals, Inc. Josephine L Feliciano reports receiving grants from Bristol Myers, AstraZeneca, and Pfizer; consulting fees from Merck, Takeda, Genentech, Coherus, AstraZeneca, Eli Lilly, and Regeneron; and payment or honoraria from Jansen. Melinda Laine Hsu reports personal fees from Regeneron, outside the submitted work. The authors report no other conflicts of interest in this work."
"This study was funded by Regeneron Pharmaceuticals, Inc."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025